Crohn’s Disease | Treatment Algorithms: Claims Data Analysis | Adult | US | 2021

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and maintain remission. Treatment of CD typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and/or biologics. However, this scenario is changing, and more physicians are prescribing biologics as first-line therapy for recently diagnosed CD patients. Among the biologics, TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) have a relatively constant patient share; however, newer biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) have witnessed a sharp increase in patient share.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CD patients
• How have Entyvio and Stelara been integrated into the treatment algorithm, and what are their source of business?
• What percentage of CD patients receive drug therapy within 365 of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of CD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Janssen, AbbVie, Takeda, UCB

Key drugs: Humira, Remicade, Entyvio, Stelara, Cimzia, biosimilar infliximab, aminosalicylates, immunosuppressants